Literature DB >> 25284154

Suberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK-LGL leukaemia.

Xiaoshen Sun1, Zainul S Hasanali, Allshine Chen, Dianzheng Zhang, Xin Liu, Hong-Gang Wang, David J Feith, Thomas P Loughran, Kailin Xu.   

Abstract

Natural killer (NK) large granular lymphocyte (LGL) leukaemia features a clonal proliferation of CD3(-) NK cells that can be classified into either aggressive or chronic categories. The NKL cell line, derived from an aggressive Asian NK cell leukaemia, and patient samples from chronic NK-LGL leukaemia were used in our study to probe for synergistic efficacy of the epigenetic drugs vorinostat (SAHA) and cladribine in this disease. We demonstrate that histone deacetylases (HDACs) are over-expressed in both aggressive and chronic NK leukaemia. Administration of the HDAC inhibitor SAHA reduces class I and II HDAC expression and enhances histone acetylation in leukaemic NK cells. In vitro combination treatment with SAHA and cladribine dose-dependently exerts synergistic cytotoxic and apoptotic effects on leukaemic NK cells. Expression profiling of apoptotic regulatory genes suggests that both compounds led to caspase-dependent apoptosis through activation of intrinsic mitochondrial and extrinsic death receptor pathways. Collectively, these data show that combined epigenetic therapy, using HDAC and DNA methyltransferase inhibitors, may be a promising therapeutic approach for NK-LGL leukaemia.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  cladribine; combined epigenetic therapy; histone deacetylation; natural killer large granular lymphocyte leukaemia; vorinostat (suberoylanilide hydroxamic acid)

Mesh:

Substances:

Year:  2014        PMID: 25284154      PMCID: PMC4304989          DOI: 10.1111/bjh.13143

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  60 in total

1.  Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia.

Authors:  Xin Liu; Lindsay Ryland; Jun Yang; Aijun Liao; Cesar Aliaga; Rebecca Watts; Su-Fern Tan; James Kaiser; Sriram S Shanmugavelandy; Andrew Rogers; Kathleen Loughran; Bailey Petersen; Jonathan Yuen; Fanxue Meng; Kendall Thomas Baab; Nancy Ruth Jarbadan; Kathleen Broeg; Ranran Zhang; Jason Liao; Thomas Joseph Sayers; Mark Kester; Thomas P Loughran
Journal:  Blood       Date:  2010-07-29       Impact factor: 22.113

2.  Energy based pharmacophore mapping of HDAC inhibitors against class I HDAC enzymes.

Authors:  Subha Kalyaanamoorthy; Yi-Ping Phoebe Chen
Journal:  Biochim Biophys Acta       Date:  2013-01

3.  Histone deacetylase inhibitors reverse CpG methylation by regulating DNMT1 through ERK signaling.

Authors:  Sibaji Sarkar; Ana L Abujamra; Jenny E Loew; Lora W Forman; Susan P Perrine; Douglas V Faller
Journal:  Anticancer Res       Date:  2011-09       Impact factor: 2.480

4.  Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma.

Authors:  Stephen E Spurgeon; Talia Pindyck; Craig Okada; Yiyi Chen; Zunqiu Chen; Elana Mater; Kamal Abbi; Elliot M Epner
Journal:  Leuk Lymphoma       Date:  2011-05-31

5.  Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.

Authors:  L M Butler; D B Agus; H I Scher; B Higgins; A Rose; C Cordon-Cardo; H T Thaler; R A Rifkind; P A Marks; V M Richon
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

6.  Large Granular Lymphocyte Leukemia.

Authors: 
Journal:  Cancer Control       Date:  1998-01       Impact factor: 3.302

7.  Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3(+) large granular lymphocyte leukemia.

Authors:  T Lamy; J H Liu; T H Landowski; W S Dalton; T P Loughran
Journal:  Blood       Date:  1998-12-15       Impact factor: 22.113

8.  Fas-ligand-induced apoptosis of respiratory epithelial cells causes disruption of postcanalicular alveolar development.

Authors:  Monique E De Paepe; Sravanthi Gundavarapu; Umadevi Tantravahi; John R Pepperell; Sheila A Haley; Francois I Luks; Quanfu Mao
Journal:  Am J Pathol       Date:  2008-06-05       Impact factor: 4.307

Review 9.  DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.

Authors:  Elizabeth A Griffiths; Steven D Gore
Journal:  Semin Hematol       Date:  2008-01       Impact factor: 3.851

10.  Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia.

Authors:  M J Robertson; K J Cochran; C Cameron; J M Le; R Tantravahi; J Ritz
Journal:  Exp Hematol       Date:  1996-02       Impact factor: 3.084

View more
  9 in total

1.  Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia.

Authors:  Zainul S Hasanali; Bikramajit Singh Saroya; August Stuart; Sara Shimko; Juanita Evans; Mithun Vinod Shah; Kamal Sharma; Violetta V Leshchenko; Samir Parekh; Thomas P Loughran; Elliot M Epner
Journal:  Sci Transl Med       Date:  2015-06-24       Impact factor: 17.956

2.  Case Report: First Report of T-Cell Large Granular Lymphocytic Leukemia With NPL-DHX9 Gene Fusion Successfully Treated With Cladribine: Clinical Experience and Literature Review.

Authors:  Qin Hu; Yunfei Li; Ying Zhang; Shusen Sun; Hui Wang; Zhiping Jiang; Sheng Deng
Journal:  Front Oncol       Date:  2022-05-06       Impact factor: 5.738

3.  mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors.

Authors:  Clare F Malone; Chloe Emerson; Rachel Ingraham; William Barbosa; Stephanie Guerra; Haejin Yoon; Lin L Liu; Franziska Michor; Marcia Haigis; Kay F Macleod; Ophélia Maertens; Karen Cichowski
Journal:  Cancer Discov       Date:  2017-09-29       Impact factor: 39.397

4.  Growth-suppressive effect of suberoylanilide hydroxamic acid (SAHA) on human oral cancer cells.

Authors:  Boonsil Jang; Ji-Ae Shin; Yong-Soo Kim; Ji-Young Kim; Ho-Keun Yi; Il-Song Park; Nam-Pyo Cho; Sung-Dae Cho
Journal:  Cell Oncol (Dordr)       Date:  2015-11-18       Impact factor: 6.730

5.  Cladribine Induces ATF4 Mediated Apoptosis and Synergizes with SAHA in Diffuse Large B-Cell Lymphoma Cells.

Authors:  Linyan Xu; Jun Jiao; Xiaoshen Sun; Wei Sang; Xiang Gao; Pu Yang; Dongmei Yan; Xuguang Song; Cai Sun; Mengdi Liu; Yuanyuan Qin; Yu Tian; Feng Zhu; Lingyu Zeng; Zhenyu Li; Kailin Xu
Journal:  Int J Med Sci       Date:  2020-05-30       Impact factor: 3.738

Review 6.  Preclinical and clinical progress for HDAC as a putative target for epigenetic remodeling and functionality of immune cells.

Authors:  Sijia Zhang; Lingjun Zhan; Xue Li; Zhenhong Yang; Yumin Luo; Haiping Zhao
Journal:  Int J Biol Sci       Date:  2021-08-03       Impact factor: 6.580

Review 7.  Epigenetic polypharmacology: from combination therapy to multitargeted drugs.

Authors:  Angel R de Lera; A Ganesan
Journal:  Clin Epigenetics       Date:  2016-10-12       Impact factor: 6.551

8.  A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia.

Authors:  Ilaria Laurenzana; Antonella Caivano; Stefania Trino; Luciana De Luca; Francesco La Rocca; Vittorio Simeon; Cristina Tintori; Francesca D'Alessio; Antonella Teramo; Renato Zambello; Antonio Traficante; Maddalena Maietti; Gianpietro Semenzato; Silvia Schenone; Maurizio Botta; Pellegrino Musto; Luigi Del Vecchio
Journal:  Oncotarget       Date:  2016-10-04

9.  Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells.

Authors:  Bolun Wang; Hui Lyu; Shanshan Pei; Deye Song; Jiangdong Ni; Bolin Liu
Journal:  Cell Cycle       Date:  2018-07-03       Impact factor: 4.534

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.